On 22 July 2024, Zydus Lifesciences announced that it has received approval in Mexico to market BhavaTM, biosimilar to Genentech’s Avastin® (bevacizumab) for metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic breast cancer, glioblastoma, renal cell carcinoma and ovarian cancer. BhavaTM is Zydus’ first approved biosimilar in Latin America. Zydus originally launched its biosimilar bevacizumab in India in 2015 (as Bryxta).
This comes after Sandoz’s Avzivi® (bevacizumab) received a positive opinion from Europe’s CHMP in May 2024 and Dr Reddy’s launched its Versavo® (bevacizumab) in the UK in March 2024, 5 years after its Indian launch and 6 years after first bevacizumab UK biosimilar approval.